AstraZeneca’s Shot Designer Seeks $613 Million Value in IPO
- Vaccitech set to offer shares for as much as $18 each
- Company is developing vaccines for cancer, HPV and hepatitis B
Photographer: SeongJoon Cho/Bloomberg
This article is for subscribers only.
The University of Oxford spinoff that designed AstraZeneca Plc’s Covid-19 vaccine is seeking a valuation as high as $613 million in its initial public offering in the U.S., a move to help fund trials for new directions in cancer and other diseases.
Vaccitech Plc is set to offer 6.5 million American depository shares for as much as $18 each and will be listed on the Nasdaq Stock Exchange, according to a filing with the U.S. Securities and Exchange Commission. The company, which will trade under the VACC ticker, will use the proceeds to advance the development of vaccines for hepatitis B virus, human papillomavirus and prostate cancer.